Acrivon Therapeutics, Inc. Common Stock (ACRV) Analyst Forecast

NASDAQ Currency in USD Disclaimer

$6.81

north_east $0.12 (1.78%)
Day's range
$6.51
Day's range
$7.18

Recent Analyst Forecasts and Stock Ratings

Date Brokerage Firm Analyst Name Price Target Price when Posted Upside/Downside
on Report Date
Details
11/14/2024 BMO Capital Etzer Darout $27.00 $7.92   240.91%
09/16/2024 BMO Capital Etzer Darout $28.00 $8.91   214.25%
08/13/2024 Oppenheimer Matthew Biegler $18.00 $7.26   147.93%
05/14/2024 Oppenheimer Matthew Biegler $21.00 $8.36   151.2%
05/14/2024 H.C. Wainwright Emily Bodnar $22.00 $8.35   163.63%
05/14/2024 BMO Capital Etzer Darout $25.00 $8.51   193.77%
04/25/2024 Piper Sandler Joseph Catanzaro $30.00 $9.20   226.09%
04/25/2024 JMP Securities Silvan Tuerkcan $17.00 $9.50   78.95%
03/28/2024 H.C. Wainwright Emily Bodnar $20.00 $7.19   178.36%
12/11/2022 Piper Sandler Joseph Catanzaro $25.00 $12.50   100%

Acrivon Therapeutics, Inc. Common Stock FAQ's

What analysts cover Acrivon Therapeutics, Inc. Common Stock?

Acrivon Therapeutics, Inc. Common Stock has been rated by research analysts at BMO Capital, Oppenheimer, H.C. Wainwright, Piper Sandler, JMP Securities, Jefferies in the past 90 days.